Hanmi Pharm’s LAPSTriple Agonist designated as orphan drug by U.S. FDA
Hanmi Pharm’s LAPSTriple Agonist designated as orphan drug by U.S. FDA
  • Lee Kap-soo
  • 승인 2020.03.06 10:28
  • 댓글 0
이 기사를 공유합니다

LAPSTriple Agonist (HM15211), which Hanmi Pharm is developing as a NASH (Non-alcoholic fatty hepatitis) treatment, has been designated as an orphan drug by the FDA based on another indication.

"The FDA has designated LAPSTriple Agonist (HM15211) as a rare drug to treat primary sclerosing cholangitis (PSC)," Hanmi Pharm said on March 5.
PSC is a rare disease with a very few patients due to chronic progressive bile identity liver disease.

Based on the multiple pharmacological effects of simultaneous stimulation of GLP-1 receptors, glucagon receptors and GIP receptors, the LAPSTriple Agonist is expected to reduce the accumulation of excessive liver bile acid and curb liver inflammation and fibrosis to dramatically improve patients' quality of life.

The FDA Designation of Orphan Drug is a system that supports the development and permission of treatments for rare and incurable diseases or life-threatening diseases. Various benefits will be granted, including tax breaks and exemption of the cost of applying for permits.

"A total of nine new drug candidates have been designated as rare by FDA and EMA," said Kwon Se-chang, CEO of Hanmi Pharm. "We will do our best to commercialize the drug based on continuous research and development for patients suffering from rare diseases."

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • URL: www.koreaittimes.com / m.koreaittimes.com. Editorial Div. 02-578-0434 / 010-2442-9446. Email: info@koreaittimes.com.
  • Publisher: Monica Younsoo Chung. CEO: Lee Kap-soo. Editor: Jung Yeon-jin. Juvenile Protection Manager: Yeon Choul-woong.
  • IT Times Canada: Willow St. Vancouver BC, Canada / 070-7008-0005.
  • Copyright(C) Korea IT Times, Allrights reserved.